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Abstract
Background: The low data publication rate for Food and Drug Administration (FDA)-approved drugs, and
discrepancies between FDA-submitted versus published data, remain a concern. We investigated the publication
statuses of sponsor-submitted clinical trials supporting recent anticancer drugs approved by the FDA, with a focus
on immune checkpoint inhibitors (ICPis).
Methods: We identified all ICPis approved between 2011 and 2014, thereby obtaining 3 years of follow-up data.
We assessed the clinical trials performed for each drug indication and matched each trial with publications in the
literature. The primary benchmark was the publication status 2 years post-approval. We examined the association
between time to publication and drug type using a multilevel Cox regression model that was adjusted for
clustering within drug indications and individual covariates.
Results: Between 2011 and 2014, 36 anticancer drugs including 3 ICPis were newly approved by the FDA. Of 19
trials investigating the 3 ICPis, 11 (58%) were published within 2 years post-approval. We randomly selected 10 of
the 33 remaining anticancer drugs; 68 of 101 trials investigating these drugs (67%) were published. Overall, the
publication rate was 66% at 2 years post-approval with a median time to publication of 2.3 years. There was no
significant difference in the time to trial publication between ICPis and other anticancer drugs (adjusted hazard
ratio [HR], 1.1; 95% confidence interval [CI], 0.8–1.7; P = 0.55). However, findings related to non-ICPis investigated
specifically in randomized phase 2 or phase 3 trials were significantly more likely to be published earlier than those
related to ICPis (adjusted HR, 7.4; 95% CI, 1.8–29.5; P = 0.005).
Conclusion: One in 3 sponsor-submitted trials of the most recently approved anticancer drugs remained unpublished
2 years post-FDA approval. We found no evidence that the drug type was associated with the time to overall trial
publication.
Keywords: Anticancer drugs, Clinical trials, Drug approval, Immune checkpoint inhibitors, Publications, United states
food and drug administration
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Background
An improved understanding of the biology of cancer has
led to remarkable progress in therapeutic approaches.
Anticancer agents developed over the last 2 decades
utilize multiple mechanisms of action including conven-
tional cytotoxic agents as well as inhibition of oncogenic
signalling pathways and angiogenesis. More recently,
‘immunotherapy’ agents that rely on immunomodulatory
mechanisms to target and destroy cancer cells, most not-
ably immune checkpoint inhibitors (ICPis), have been
developed.
The first ICPi approved by the United States Food
and Drug Administration (FDA) was ipilimumab, a fully
humanized immunoglobulin G1 monoclonal antibody
that blocks cytotoxic T-lymphocyte antigen [1]. Pem-
brolizumab and nivolumab were the first ICPis that tar-
get programmed cell death protein 1; they showed high
response rates with favourable toxicity profiles and
were approved for treating metastatic melanoma in
2014 [2, 3]. The notable successes of these pivotal trials
may have led to unrealistically high expectations among
patients and clinicians, as more recent studies have
shown that only a subset of patients exhibit durable re-
sponses, and existing checkpoint-blocking monother-
apies seldom lead to complete remission [4–6]. These
findings have prompted the search for next-generation
ICPis as well as evaluations of their combinations with
other biologic agents [7].
Anticancer drugs are approved by the FDA based on
substantial evidence of clinical benefit from adequate
and well-controlled clinical trials. Their efficacies are
demonstrated by prolonging patients’ survival and im-
proving their quality of life by preventing or ameliorat-
ing cancer-related symptoms. Sponsors of a new drug
are required to submit all data to the FDA, including
complete protocols, protocol revisions, and data from
successful and failed trials. Once the drug is approved,
the FDA produces a ‘Summary Basis of Approval’ docu-
ment that contains synopses and evaluations of clinical
data and statistical analyses performed by FDA medical
officers during the approval process. These documents
contain detailed efficacy and safety data that are relevant
to drug approval but are not necessarily intended to be
shared with general evidence users such as clinicians,
patients, and policymakers. In this context, the peer-
reviewed medical literature has a powerful and import-
ant role in disseminating information relevant to both
clinicians and the public. Nevertheless, the publication
rates of sponsor-submitted trial results for drugs ap-
proved by the FDA have been low, and discrepancies
exist between original trial data submitted to the FDA
and data found in published trials [8–10]. The lack of
timely and complete dissemination of clinical trial data
can lead to unnecessary duplication of research and
impair evidence-based clinical decision-making, thus
violating ethical obligations. Delayed and incomplete dis-
semination can have particularly deleterious effects on
cancer patients.
Thus, we performed a comprehensive examination
of the publication statuses of trials submitted by the
sponsors of investigating the most recent FDA-
approved anticancer drugs, with a focus on ICPis. As
we hypothesized that the growing enthusiasm around
ICPis may lead to expediting the publication of data
involving these drugs, we further evaluated the role of
the drug types in the time taken to publish their as-
sociated clinical trial results.
Methods
The protocol for this meta-epidemiological investigation




We used the Drugs@FDA database to identify all ICPis
that were newly approved for cancer treatment by the
FDA between 2011 (the year the first ICPi was approved
by the FDA) and 2014 (thus assuring a follow-up of at
least 3 years post-approval). All other anticancer drugs
approved by the FDA between 2011 and 2014 were also
identified, 10 of which were randomly selected for com-
parison using the Excel software (Microsoft Corp, Red-
mond, WA, USA). We included only new drugs against
novel molecular targets and excluded those that are pre-
ventative or palliative.
Identification of clinical trials
We retrieved the FDA Summary Basis for Approval of
each drug and assessed medical review documents to
identify clinical trials submitted by the sponsor. The med-
ical reviews included an overview of safety and efficacy, an
outline of the data sources, integrated summaries of safety
and efficacy, and (where relevant) a description of individ-
ual clinical trials. We included trials that were or were not
covered by the Food and Drug Administration Amend-
ments Act of 2007 (FDAAA) mandate for submission of
results (efficacy trials: phase 2–3) [11], because the nonpu-
blication of any clinical trial stage has potentially deleteri-
ous impacts on patients and clinicians, represents a waste
of resources, and violates ethical imperatives to share
results. Ethical board review and informed consent were
not required for this survey of publicly available databases
and articles in which aggregated data were inherently
anonymized.
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Search strategy and data extraction
First, we recorded the following characteristics for each
submitted trial when available in FDA documents: the
drug name (generic and trade), initial approval date,
approval characteristics (FDA review process and ap-
proval pathway), drug target, delivery method, dosage
and evaluation schedules, indication, number and loca-
tion of study sites, sponsors’ and principal investigators’
names, authors’ industry affiliations, study phase, study
type (superiority, non-inferiority, or equivalence trial),
number of arms, control conditions, number of study
participants, primary and secondary outcomes, sample
size in the primary analysis, and effect size of each pri-
mary outcome. Second, using the above information as
search terms, we electronically searched PubMed, Goo-
gle/Google Scholar, and their sponsors’ websites to
obtain study identifiers (ClinicalTrials.gov registry
[NCT] number and/or trial unique ID) for each trial
identified in the FDA review documents.
Next, we searched ClinicalTrials.gov and the World
Health Organization International Clinical Trials Regis-
try Platform with the study identifier to obtain the fol-
lowing detailed information for each trial: dosing
schedules, number and location of study centres, princi-
pal investigators’ names, authors’ industry affiliations,
study phase, study type (superiority, non-inferiority, or
equivalence trial), number of arms, control conditions,
planned sample sizes, compared parameters, number of
study participants, primary and secondary outcomes,
sample size in the primary analysis, effect size of the pri-
mary outcome, statistical significance of the primary
outcome (P < 0.05 or confidence interval [CI] excluding
those with ‘no difference’; or if the study was a non-
inferiority evaluation, the CI including ‘no difference’
and excluding the prespecified margin described in the
protocol; or if the study was an equivalence evaluation,
the CI between the no difference and prespecified mar-
gin). Nonsignificant or null results were defined as P >
0.05 or a CI including ‘no difference’, or else a CI includ-
ing the prespecified margin if the study investigated
non-inferiority or its equivalent. We also noted whether
the trial was randomized and/or double-blinded. Miss-
ing, unclear, or important additional data were requested
from sponsors or primary study authors.
Publication matching
We searched PubMed, Google/Google Scholar, and their
sponsors’ websites to match each identified trial to pub-
lications in the medical literature between June and
August 2018. We also searched abstracts in the proceed-
ings of relevant periodic meetings as well as reference
lists. Studies in all languages were reviewed as abstracts
or full texts. Trials identified in FDA documents were
matched to publications based on the following
characteristics: study identifier (NCT number and/or
trial ID), drug name, sample size, dosing schedules, arm
number, primary and secondary outcome measures, and
statistical significance or estimated effect of the primary
outcome results. The publication type of each trial was
recorded as follows: (1) full publication, (2) full report,
(3) partial publication, (4) conference abstract, (5) none
(neither published nor reported, but verified), or (6) un-
clear (no information found). Only original research re-
ports in full peer-reviewed journals were considered full
publications and included all the primary outcomes pre-
defined in the protocol (#1 above) or partial publications
containing incomplete descriptions of the prespecified
primary outcomes (#3 above). For trials that were termi-
nated early because of perceived effectiveness, only ori-
ginal research reports were considered full publications
(#1 above) including all findings and results. If all the
predefined primary outcomes were available in Clinical-
Trials.gov or the sponsors’ websites, the trial was consid-
ered a full report (#2 above). If multiple publications
were found for the same trial, we prioritized the category
with the smaller number; for example, if a trial was fully
reported (#2 above) and published (#1 above), then it
was categorized as a full publication (#1 above). If trials
remained unmatched to a publication, we contacted the
sponsors or authors to clarify their publication statuses.
Four reviewers (KO, YK, YT, and YT) screened all ab-
stracts and full-text articles independently. Disagree-
ments were resolved by discussion; otherwise, a fifth
independent reviewer (TAF) arbitrated.
Statistical analysis
We performed descriptive statistics of the included trials
stratified by drug type (ICPis vs. other anticancer drugs).
The primary endpoint was the rate of ‘full publication’
within 2 years after FDA approval [9]; we also analysed
the publication statuses at 0 and 3 years. Moreover, we
evaluated whether study identifiers were reported to de-
termine the articles’ discoverability; for example, once a
trial’s NCT number is published as part of the original
journal article, it is automatically identified and indexed
by ClinicalTrials.gov.
Next, we examined the influence of study phase and
drug type on the time from FDA approval to ‘full publi-
cation’ using log-rank tests. In time-to-event analyses,
trials that were not published were censored, and time 0
was defined as the date of FDA approval per the Admin-
istration’s documents. Trials published before their FDA
approval date were considered published at time 0.
We further performed multivariable analysis of the
association between drug type/study phase and time to
publication using a multilevel Cox regression model that
was adjusted for clustering within drug indications and
potential confounders, including sample size and
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ethnicity. We classified trials as ‘smaller’ if the sample
size was smaller than the median value of all the studies
combined; otherwise, they were deemed ‘larger’.
We conducted a limited number of prespecified sub-
group and sensitivity analyses and examined the time
to publication among all as well as randomized phase
2/3 trials. The sensitivity analyses employed a multi-
level ordered logistic regression model to evaluate the
association between drug type and publication status
according to the abovementioned categories (categories
Fig. 1 Flowchart showing the selection of new drugs and supporting trials ICPi, immune checkpoint inhibitor
Table 1 Characteristics of included trials by anticancer drug type
ICPi (n = 3) Other anticancer drug (n = 10)
Included drugs (n) Ipilimumab, Pembrolizumab, Nivolumab Abiraterone acetate, Brentuximab vedotin, Bosutinib,




Priority review 0, orphan drug 3 (100%),
breakthrough therapy 2 (67%), accelerated
approval 2 (67%)
Priority review 4 (40%), orphan drug 7 (70%),
breakthrough therapy 1 (10%), accelerated
approval 4 (40%)
ICPi trials (n = 19) Other anticancer drug trials (n = 101)
Study phase, n (%)
Phase 1 5 (26) 42 (42)
Phase 2 9 (47) 48 (48)
Phase 3 5 (26) 11 (11)
Efficacy study, n (%) 11 (58) 18 (18)
Randomized study, n (%) 12 (63) 28 (28)
Double-blinded study, n (%) 7 (37) 13 (13)
Multi-country study, n (%) 12 (63) 52 (51)
Author affiliation with industry, n (%) 18 (95) 82 (81)
Sample size, median (IQR) 284 (127–676) 58 (37–121)
Statistically significant outcomeª, n (%) 8 (42) 10 (10)
Reporting of adverse events, n (%) 19 (100) 91 (90)
Selective outcome reporting, n (%) 6 (32) 21 (21)
ICPi immune checkpoint inhibitor, IQR interquartile range
ªAt least 1 of the primary outcomes was statistically significant
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5 and 6 were combined) at 0, 2, and 3 years with adjust-
ment for clustering within drug indications and individ-
ual covariates. Additionally, we performed a post-hoc
analysis of the “full publication” rate at 2 years post-
approval of trials that supported only the drug indica-
tions for which priority review was granted by the FDA;
this was to determine the impact of such priority review
on the time to publication. Statistical significance was
set at P < 0.05 (2-tailed test). We used STATA version




The FDA approved 3 ICPis and 33 other anticancer
drugs between 2011 and 2014; 10 of the latter were ran-
domly selected for this study. We identified 140 trials in
the FDA review documents supporting their drug ap-
proval; 120 trials (19 for ICPis and 101 for other antican-
cer drugs) were ultimately eligible for this study (Fig. 1).
Table 1 summarizes the characteristics of the included
drugs and their supporting trials as submitted by the
sponsor. All 3 ICPis (100%) received orphan drug status;
2 (67%) were breakthrough therapies and 2 (67%) re-
ceived accelerated approval. Among the 10 non-ICPis,
orphan drug and breakthrough therapy statuses were
granted to 7 (70%) and 1 (10%), respectively, while prior-
ity review and accelerated approval were granted to 4
drugs each (40%). ICPi trials were more likely to be late-
phase, randomized, and double-blinded studies with lar-
ger cohorts. Nearly all trials reported adverse events, and
a majority had authors affiliated with the pharmaceutical
industry. Over 20% did not report all predefined out-
comes (i.e. engaged in selective outcome reporting).
Study identifiers
Eighteen of 89 published trials (20%) lacked a study
identifier (Table 2). All phase 3 trial articles and those
reporting a statistically significant primary outcome in-
cluded an NCT number and/or trial ID. Notably, all arti-
cles on ICPi trials except 1 also described the study
Table 2 Characteristics of fully published trials according to whether the study identifier is present
Presence or absence of study identifier in the published article
Yes (n = 71) No (n = 18)
Study phase, n (%)
Phase 1 17 (24) 12 (67)
Phase 2 38 (54) 6 (33)
Phase 3 16 (23) 0
Drug type, n (%)
Immune checkpoint inhibitors 18 (25) 1 (6)
Other anticancer drugs 53 (75) 17 (94)
Sample size, median (interquartile range) 102 (53–345) 42 (37–56)
Multi-country study, n (%) 46 (65) 5 (28)
Author affiliation with industry, n (%) 71 (100) 16 (89)
Statistically significant outcomeª, n (%) 17 (24) 0
Reporting of adverse events, n (%) 71 (100) 18 (100)
Selective outcome reporting, n (%) 8 (11) 7 (39)
ªAt least 1 of the primary outcomes was statistically significant
Table 3 Publication status of included trials at 0, 2, and 3 years post-approval
0 years 2 years 3 years
Publication status, n (%) ICPi trials Other anticancer
drug trials
All trials ICPi trials Other anticancer
drug trials
All trials ICPi trials Other anticancer
drug trials
All trials
Full publication 6 (32) 35 (35) 41 (34) 11 (58) 68 (67) 79 (66) 15 (79) 71 (70) 86 (72)
Full report 0 10 (10) 10 (8) 2 (11) 12 (12) 14 (12) 2 (11) 11 (11) 13 (11)
Partial publication 5 (26) 5 (5) 10 (8) 5 (26) 6 (6) 11 (9) 2 (11) 7 (7) 9 (8)
Conference abstract 2 (11) 14 (14) 16 (13) 0 3 (3) 3 (3) 0 2 (2) 2 (2)
None 6 (32) 35 (35) 41 (34) 1 (5) 10 (10) 11 (9) 0 8 (8) 8 (7)
Unclear 0 2 (2) 2 (2) 0 2 (2) 2 (2) 0 2 (2) 2 (2)
ICPi immune checkpoint inhibitor
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identifier; however, 24% of the articles on anticancer
drug trials had no such identifiers.
Publication status
Table 3 shows the publication status at 0, 2, and 3 years
post-FDA approval. Overall, 41 trials (34%) had not been
published in full by 2 years post-approval; over 40% of
ICPi trials remained unpublished. We categorized 2 tri-
als for other anticancer drugs as unclear because,
although we identified publications describing their
results, the trials themselves had not been documented
in any registry and no protocol was available. Therefore,
we were unable to identify their primary outcomes and
could not determine their publication status according
to our classification.
Trial characteristics associated with time to publication
The median time from FDA approval to ‘full publication’
was 2.3 years (interquartile range, 6.7 months to not es-
timable). Figure 2 shows the cumulative proportion of
Fig. 2 Daily publications of trials supporting the approval of new anticancer drugs (a) Daily publications by study phase. (b) Daily publications by
drug type. ICPi, immune checkpoint inhibitor
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fully published trials by phase and drug type. Neither the
trial phase nor the drug type significantly affected the
time to publication.
A multivariable Cox regression model analysis con-
firmed no significant difference in the time to trial publi-
cation between ICPis and other anticancer drugs
(adjusted hazard ratio [HR] of other anticancer drugs,
1.1; P = 0.55). However, when controlled for con-
founders, phase 2 or 3 trials were published faster than
phase 1 trials (adjusted HR, 1.7; P = 0.02) (Table 4).
Subgroup analyses
Figure 3 shows the cumulative proportion of full pub-
lications among all and randomized-only phase 2/3
trails. Randomized phase 2 and 3 trials of other anti-
cancer drugs were published significantly earlier than
ICPi trials (P = 0.006).
Sensitivity analyses
Sensitivity analyses confirmed that drug type was not
associated with the ordered publication status at 0, 2,
or 3 years post-approval (adjusted odds ratio [OR] of
other anticancer drugs, 1.1, 1.4, and 0.6 [P = 0.92,
0.58, and 0.49], respectively). However, the study
phase was significantly associated with the ordered
publication status at 2 and 3 years (adjusted OR of
phase 2 or 3 trials, 3.1 and 4.6 [P = 0.04 and 0.01], re-
spectively); these data are supplied in an additional
table [See Additional file 1]. Although we found no
association between the drug type and time to publi-
cation of phase 2 and 3 trials (adjusted HR, 1.1, P =
0.95), other anticancer drugs were associated with
significantly earlier publication of randomized phase 2
and 3 trials (adjusted HR, 17.7, P < 0.0001); these data
are supplied in additional tables [See Additional file 2
and Additional file 3].
Post-hoc analyses
Of the 46 trials supporting 4 drug indications to which
priority review was granted by the FDA, 16 (35%) had
not been published in full at 2 years post-approval.
Discussion
The median time from FDA approval to full publication
of the 120 trials supporting the 3 ICPis and 10 randomly
selected non-ICPi drugs was 2.3 years, and one-third of
the trials remained unpublished 2 years post-approval.
Although we found no association between any drug
type and time to publication overall, the publication of
randomized phase 2 and 3 trials for ICPis took longer
than for other anticancer drug types. Interestingly, the
publication rates of all trials were very similar, including
for those supporting drug indications to which priority
review was granted by the FDA.
A previous study found that over half of the trials sup-
porting new drugs approved between 1998 and 2000
remained unpublished ≥5 years after approval, and that
statistically significant results were more likely to be
reported [9]. Another study found that nearly half of
phase 2 and 3 trials for antidepressant agents approved
between 1987 and 2004 were unpublished, and possible
selective reporting biases were present [12]. Additionally,
97% of clinical trials for cardiovascular disease and
diabetes drugs were published in the peer-reviewed
literature after the FDAAA was implemented [13].
The publication rate revealed in our investigation was
higher than those found in 2 earlier studies performed
before the FDAAA implementation [9, 12]. The statis-
tical significance of the results was not associated with
earlier trial publication, suggesting an improvement in
the dissemination and transparency of trial results
related to FDA approval. However, the overall publica-
tion rate of 66% remains insufficient to satisfy the
responsibilities of medical and academic enterprises.
Recent research on all pharmaceutical and biopharma-
ceutical trials registered with clinicaltrials.gov demon-
strated that publication rates varied substantially
depending on the disease area, and that oncology-
related trials had the lowest publication rates [14].
Stakeholders, including researchers and sponsors as
well as journals, ethical committees, and governments,
ought to invest additional effort to promote the timely
and complete dissemination of clinical trial findings,
especially those related to oncology.
Including all the clinical trial that supported drug ap-
proval, as required by the Declaration of Helsinki [15],
enabled us to quantify the differences in the timing of
trial publication across study phases. We also clarified
Table 4 Characteristics associated with full publication: Cox
proportional hazards model analysis
HR (95% CI) P-value
Drug type
ICPi ref.
Other anticancer drugs 1.1 (0.8–1.7) 0.55
Study phase
Phase 1 ref.
Phase 2 or 3 1.7 (1.1–2.6) 0.02
Multi-country study
No ref.
Yes 1 (0.4–2.2) 0.95
Sample size
Smaller ref.
Larger 1.4 (0.8–2.2) 0.16
ICPi immune checkpoint inhibitor, HR hazard ratio, CI confidence interval,
ref. reference
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the differences in the discoverability and accessibility of
published articles according to study phases. Although
previous investigators have described the underreporting
of trial registration numbers in biomedical publications
related to randomized clinical trials (RCTs) [16, 17], the
current study expanded the scope of research to all clin-
ical trials (including RCTs and non-RCTs), and found
that such study identifiers were less frequently included
in articles describing earlier-phase trials. This suggests
that systematically searching for trials (especially earlier
ones) using study identifiers is unreliable and could re-
sult in undercounting publications and in incomplete
data dissemination. Authors and sponsors are encour-
aged to include study identifiers in all their articles re-
gardless of the study phase or statistical significance of
study outcomes.
The results of randomized phase 2 and 3 trials are
usually considered ‘gold standard’ evidence of drug effi-
cacy, and thus directly affect both drug marketing
approval as well as drug sales. In our study, subgroup
Fig. 3 Daily publications of phase 2 and 3 trials supporting the approval of new anticancer drugs (a) Daily publications of all phase 2 and 3 trials
by drug type. (b) Daily publications of randomized-only phase 2 and 3 trials by drug type. ICPi, immune checkpoint inhibitor
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analyses of randomized phase 2 and 3 trials showed that
the drug type (ICPi vs. non-ICPi) was associated with
time to publication; the difference remained significant
after adjusting for trial-level confounders. We speculate
that the novel ICPi mechanism of action may have influ-
enced each step of the trials’ publication processes, espe-
cially as various stakeholders were involved. Recently
disclosed details of sponsored trial publication histories
indicated that some industry sponsors require the timely
submission of all trial results for publication [18, 19].
Evaluators of the dissemination and transparency of
clinical trial results should consider such publication-
related policies.
Our study had several limitations. First, it was re-
stricted to trials supporting FDA approval of antican-
cer drugs; therefore, our results are not generalizable.
Second, because we focused on recently approved
drugs, follow-up times were limited; as such, longer
follow-up may yield additional publications (although
they may not qualify as timely). Third, our analysis
may have been statistically underpowered to detect
significant relationships or differences given the lim-
ited number of trials. Fourth, it remains possible that
we missed some published studies. Lastly, as is inher-
ent in all observational studies, causal inferences can-
not be made, and additional unmeasured variables
may explain the differences in times to publication.
However, our study also has several strengths, such as
the inclusion of all trials irrespective of study phase as
well as rigorous search algorithms and thorough statis-
tical analyses.
In conclusion, our results showed that incomplete
transparency and delays in disseminating sponsor-
submitted clinical trials supporting FDA drug approval
are still prevalent. Further efforts and continuous moni-
toring are necessary to improve the timely and complete
publication of clinical trial results.
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